Musculoskeletal involvement in sarcoidosis;Acometimento músculo-esquelético na sarcoidose

Jornal Brasileiro de Pneumologia

Volumn 40, Issue 2, 2014, Pages 175-182

  Nessrine, Akasbi ^a   Zahra, Abourazzak Fatima ^a   Taoufik, Harzy ^a  

^a HASSAN II UNIVERSITY HOSPITAL   (Morocco)

Author keywords

Bone and bones; Joints; Muscles; Sarcoidosis

Indexed keywords

CORTICOSTEROID; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

FEMALE; HUMAN; MALE; MUSCULOSKELETAL DISEASE; REVIEW; SARCOIDOSIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MUSCULOSKELETAL DISEASES; SARCOIDOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900548797     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37132014000200012     Document Type: Review

References (51)

1. Fayad F, Liote F, Berenbaum F, Orcel P, Bardin T. Muscle involvement in sarcoidosis: a retrospective and followup studies. J Rheumatol. 2006;33(1):98-103. PMid:16395757
2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736-55. PMid:10430755. http://dx.doi.org/10.1164/ajrccm.160.2.ats4-99
3. Sweiss NJ, Curran J, Baughman RP. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. Clin Dermatol. 2007;25(3):341-6. PMid:17560312. http://dx.doi.org/10.1016/j.clindermatol.2007.03.012
4. Tozman EC. Sarcoidosis: clinical manifestations, epidemiology, therapy, and pathophysiology. Curr Opin Rheumatol. 1991;3(1):155-9. PMid:2043441. http://dx.doi.org/10.1097/00002281-199102000-00021
5. Tazi A. Update on sarcoidosis [Article in French]. Rev Pneumol Clin. 2005;61(3):203-10. http://dx.doi.org/10.1016/S0761-8417(05)84813-8
6. Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, Gaede KI, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet. 2008;40(9):1103-6. PMid:19165924. http://dx.doi.org/10.1038/ng.198
7. Smith G, Brownell I, Sanchez M, Prystowsky S. Advances in the genetics of sarcoidosis. Clin Genet. 2008;73(5):401-412. PMid:18312452. http://dx.doi.org/10.1111/j.1399-0004.2008.00970.x
8. Eschard JP, Etienne JC. Osteoarticular manifestations of sarcoidosis [Article in French]. Rev Med Interne. 1994;15 Suppl 3:305S-307S. PMid:7863135
9. Torralba KD, Quismorio FP Jr. Sarcoid arthritis: a review of clinical features, pathology and therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(2):95-103. PMid:12870718
10. Zisman DA, Shorr AF, Lynch JP 3rd. Sarcoidosis involving the musculoskeletal system. Semin Respir Crit Care Med. 2002;23(6):555-70. PMid:16088651. http://dx.doi.org/10.1055/s-2002-36520
11. Löfgren S. Primary pulmonary sarcoidosis. I. Early signs and symptoms. Acta Med Scand. 1953;145(6):424-31. PMid:13079656. http://dx.doi.org/10.1111/j.0954-6820.1953.tb07039.x
12. Ma-á J, Gómez-Vaquero C, Montero A, Salazar A, Marcoval J, Valverde J, et al. Löfgren's syndrome revisited: a study of 186 patients. Am J Med. 1999;107(3):240-5. http://dx.doi.org/10.1016/S0002-9343(99)00223-5
13. Govindarajan V, Agarwal V, Aggarwal A, Misra R. Arthritis in sarcoidosis. J Assoc Physicians India. 2001;49:1145-7. PMid:11996432
14. Fodor L, Bota IO, Fodor M, Ciuce C. Sarcoid flexor tenosynovitis as a single early manifestation of the disease. J Plast Reconstr Aesthet Surg. 2012;65(8):e217-9. PMid:22472050. http://dx.doi.org/10.1016/j. bjps.2012.03.024
15. Moore SL, Teirstein AE. Musculoskeletal sarcoidosis: spectrum of appearances at MR imaging. Radiographics. 2003;23(6):1389-99. PMid:14615552. http://dx.doi.org/10.1148/rg.236025172
16. Awada H, Abi-Karam G, Fayad F. Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Pract Res Clin Rheumatol. 2003;17(6):971-87. PMid:15123046. http://dx.doi.org/10.1016/j.berh.2003.09.005
17. Thelier N., Allanore Y. Localisations ostéoarticulaires de la sarcoïdose. EMC -Appareil locomoteur. 2009:1-11 [Article 14-027-C-10]. http://dx.doi.org/10.1016/S0246-0521(09)48227-5
18. Baldi BG, Pereira CA, Rubin AS, Santana AN, Costa AN, Carvalho CR, et al. Highlights of the Brazilian Thoracic Association guidelines for interstitial lung diseases. J Bras Pneumol. 2012;38(3):282-91. PMid:22782597. http://dx.doi.org/10.1590/S1806-37132012000300002
19. Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn MF, Malaise MG. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol. 1995;34(7):642-4. PMid:7670783. http://dx.doi.org/10.1093/rheumatology/34.7.642
20. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factoralpha therapy. Ann Intern Med. 2001;135(1):27-31. http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00010
21. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum. 2003;48(12):3542-3. PMid:14674007. http://dx.doi.org/10.1002/art.11357
22. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol. 2003;30(8):1864-7. PMid:12913948
23. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006;25(4):596-7. PMid:16247590. http://dx.doi.org/10.1007/s10067-005-0037-9
24. Toussirot E, Pertuiset E. TNF blocking agents and sarcoidosis: an update [Article in French]. Rev Med Interne. 2010;31(12):828-37. PMid:20510487. http://dx.doi.org/10.1016/j.revmed.2010.02.007
25. Vigne C, Tebib JG, Pacheco Y, Coury F. Sarcoïdose: un effet secondaire sous-estimé et éventuellement grave du traitement par anti-TNF alpha. Rev Rhum. 2013;80(1):90-3. http://dx.doi.org/10.1016/j.rhum.2012.06.011
26. Belkhou A, Younsi R, El Bouchti I, El Hassani S. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine. 2008;75(4):511-2. PMid:18562234. http://dx.doi.org/10.1016/j.jbspin.2008.01.025
27. Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther. 2009;9(7):889-95. PMid:19463076. http://dx.doi.org/10.1517/14712590903018837
28. Barnard J, Newman LS. Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol. 2001;13(1):84-91. http://dx.doi.org/10.1097/00002281-200101000-00014
29. Flipo RM, Cotton A. Sarcoidosic dactylitis [Article in French]. Rev Med Interne. 1995;16(9):724-5. http://dx.doi.org/10.1016/0248-8663(96)80778-8
30. Rúa-Figueroa I, Gantes MA, Erausquin C, Mhaidli H, Montesdeoca A. Vertebral sarcoidosis: clinical and imaging findings. Semin Arthritis Rheum. 2002;31(5):346-52. PMid:11965598. http://dx.doi.org/10.1053/sarh.2002.31553
31. Mostard RL, Prompers L, Weijers RE, van Kroonenburgh MJ, Wijnen PA, Geusens PP, et al. F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med. 2012;37(1):21-5. PMid:22157023. http://dx.doi.org/10.1097/RLU.0b013e3182335f9b
32. Smith K, Fort JG. Phalangeal osseous sarcoidosis. Arthritis Rheum. 1998;41(1):176-9. http://dx.doi.org/10.1002/1529-0131(199801)41:1176::AID-ART223.0.CO;2-Y
33. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064-71. PMid:15764796. http://dx.doi.org/10.1378/chest.127.3.1064
34. Fayad F, Duet M, Orcel P, Lioté F. Systemic sarcoidosis: the "leopard-man" sign. Joint Bone Spine. 2006;73(1):109-12. PMid:16256397. http://dx.doi.org/10.1016/j. jbspin.2005.04.007
35. Sharma OP. Fatigue and sarcoidosis. Eur Respir J. 1999;13(4):713-4. PMid:10362027. http://dx.doi.org/10.1034/j.1399-3003.1999.13d01.x
36. Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J. 1999;13(4):718-22. PMid:10362029. http://dx.doi.org/10.1034/j.1399-3003.1999.13d03.x
37. Tohme-Noun C, Le Breton C, Sobotka A, Boumenir ZE, Milleron B, Carette MF, et al. Imaging findings in three cases of the nodular type of muscular sarcoidosis. AJR Am J Roentgenol. 2004;183(4):995-9. PMid:15385292. http://dx.doi.org/10.2214/ajr.183.4.1830995
38. Akasbi N, Tahiri L, Daoudi A, Bendahou M, Harzy T. Frohse's arcade syndrome revealing sarcoidosic myopathy. Joint Bone Spine. 2011;78(5):522-3. PMid:21549630. http://dx.doi.org/10.1016/j.jbspin.2011.03.007
39. Zisman DA, Biermann JS, Martinez FJ, Devaney KO, Lynch JP 3rd. Sarcoidosis presenting as a tumorlike muscular lesion. Case report and review of the literature. Medicine (Baltimore). 1999;78(2):112-22. http://dx.doi.org/10.1097/00005792-199903000-00002
40. Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie MJ, Round J, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983;18(2):155-66. http://dx.doi.org/10.1111/j.1365-2265.1983.tb03198.x
41. Maples CJ, Counselman FL. Lupus pernio. J Emerg Med. 2007;33(2):187-9. PMid:17692772. http://dx.doi.org/10.1016/j.jemermed.2006.11.015
42. Mansour MJ, Al-Hashimi I, Wright JM. Coexistence of Sjögren's syndrome and sarcoidosis: a report of five cases. J Oral Pathol Med. 2007;36(6):337-41. PMid:17559494. http://dx.doi.org/10.1111/j.1600-0714.2007.00530.x
43. Visser H, Vos K, Zanelli E, Verduyn W, Schreuder GM, Speyer I, et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis. 2002;61(6):499-504. PMid:12006321 PMCid:PMC1754119. http://dx.doi.org/10.1136/ard.61.6.499
44. Baughman RP, Janovcik J, Ray Et Al M. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):113-20. PMid:24071882
45. Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford). 2000;39(7):707-13. http://dx.doi.org/10.1093/rheumatology/39.7.707
46. Rajakariar R, Sharples EJ, Raftery MJ, Sheaff M, Yaqoob MM. Sarcoid tubulo-interstitial nephritis: long-term outcome and response to corticosteroid therapy. Kidney Int. 2006;70(1):165-9. PMid:16688117. http://dx.doi.org/10.1038/sj.ki.5001512
47. Moudgil A, Przygodzki RM, Kher KK. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol. 2006;21(2):281-5. PMid:16362392. http://dx.doi.org/10.1007/s00467-005-2086-3
48. Ahmed MM, Mubashir E, Dossabhoy NR. Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab. Clin Rheumatol. 2007;26(8):1346-9. PMid:16850114. http://dx.doi.org/10.1007/s10067-006-0357-4
49. Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int. 1990;5(3 Pt 1):164-8 PMid:2288818
50. Sweiss NJ, Lower EE, Korsten P, Niewold TB, Favus MJ, Baughman RP. Bone health issues in sarcoidosis. Curr Rheumatol Rep. 2011;13(3):265-72. PMid:21327743 PMCid:PMC3311464. http://dx.doi.org/10.1007/s11926-011-0170-1
51. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515-26. PMid:20662044. http://dx.doi.org/10.1002/acr.20295